VALBONNE, France--( BUSINESS WIRE )--Regulatory News: TxCell SA (Paris:TXCL) (FR0010127662 TXCL), a biotechnology company developing innovative, personalized cell immunotherapies using regulatory T-cells for the treatment of severe chronic ... Business Wire, 1 month ago
More from: Equities.com, Nasdaq...and 3 other sources
Merck, the leading healthcare, life sciences and technology company established in Germany in 1668, extended its partnership with the Weizmann Institute of Science in Rehovot on Tuesday by signing a new framework agreement that builds on a ...Jerusalem Post, 2 months ago MERCK KGAA : and Weizmann Institute Sign New Framework Agreement on Research Collaboration 4 Traders, 2 months ago MERCK : and Weizmann Institute Sign New Framework Agreement on Research Collaboration 4 Traders, 2 months ago
Global Biotherapeutics Market Report: Novel Formulation and Delivery Approaches with Focus on Antibodies and Proteins - Research and Markets
/PRNewswire/ Research and Markets has announced the addition of the "Biotherapeutics: Novel Formulation and Delivery Approaches (Focus on Antibodies and Proteins)" report to their offering. Biopharmaceuticals is currently one of the fastest ...Pharmacy Choice, 4 weeks ago Biotherapeutics Market Report: Novel Formulation and Delivery Approaches - Focus on Antibodies and Proteins Financial Buzz, 4 weeks ago Magnetic Resonance Imaging Systems Devices Market Research Assessment, 2015 Before It's News, 2 months ago Global Peptide Therapeutics in Metabolic Disorders 2016-2025 BioSpace, 2 months ago
Scientists at the Weizmann Institute may have found the cure for prostate cancer, at least if it is caught in its early stages via a drug that doctors inject into cancerous cells and treat with infrared laser illumination. Using a therapy ...The Times Of Israel, 3 weeks ago Revolutionary therapy for prostate cancer coming to Europe Israel 21c, 2 weeks ago
BiondVax Pharma (BVXV) to Post FY2015 Earnings of ($0.03) Per Share, Zacks Investment Research Forecasts
BiondVax Pharma (NASDAQ:BVXV) Zacks Investment Research issued their FY2015 earnings per share estimates for BiondVax Pharma in a research note issued on Monday, according to Zacks Investment Research. Zacks Investment Research analyst D. Bautz ...American Banking News, 2 months ago Zacks Investment Research Reiterates Outperform Rating for BiondVax Pharma (BVXV) WKRB News, 2 months ago
CELL SOURCE, INC. - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
This Management Discussion and Analysis ("MD&A") contains "forward-looking statements," which represent our projections, estimates, expectations or beliefs concerning among other things, financial items that relate to management's future plans or ...Pharmacy Choice, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!